Navigation Links
Pharmaceutical Litigation Partner James Stronski Joins Crowell & Moring
Date:5/4/2011

WASHINGTON, May 4, 2011 /PRNewswire-USNewswire/ -- Crowell & Moring LLP is pleased to announce the addition of partner James K. Stronski to the firm's Intellectual Property Group. Based in the New York office, Stronski is an intellectual property litigator with extensive experience handling cases involving the so-called "Hatch-Waxman" Amendments to the Federal Food Drug & Cosmetic Act, as well as patent, trade secret, trademark, copyrights, and unfair competition matters. Stronski will be joined by counsel Chiemi D. Suzuki. They join the firm from Frommer Lawrence & Haug LLP.

"Jim has significant first-chair patent litigation experience, having successfully handled a variety of bench and jury trials. He is the perfect complement to our New York office and our growing pharmaceutical litigation and life sciences practice. Jim's versatility and experience in handling high-stakes matters is a tremendous asset to our clients," said Mark Supko, chair of the firm's Intellectual Property Group.

Stronski has been litigating cases primarily in federal courts nationwide for over 20 years. He focuses his practice on the representation of generic pharmaceutical companies in patent litigation related to "Hatch-Waxman" matters. These particular cases involve challenges to pharmaceutical patents by companies wanting to introduce generic versions of patented drugs. Stronski has first chaired trials, evidentiary preliminary injunction and Markman hearings, and has argued before the Federal Circuit.  

With considerable experience in both bench and jury trials, preliminary injunction motions and appellate practice, he has represented clients in a wide range of industries including pharmaceuticals, the internet, consumer products, plastics, high-tech composites, and semiconductor manufacturing equipment. He also has first chaired cases, including through trial, before the Trademark Trial and Appeal Board (TTAB), and advises clients on trademark infringement and clearance issues.

"Crowell & Moring is a premier litigation firm that has built a large, first-class Intellectual Property Group, serving the needs of clients internationally. I am looking forward to being part of the firm and expanding its pharmaceutical patent litigation practice. Beyond the strength of Crowell & Moring's practices, I was attracted to the firm because it has been at the forefront in using alternative fee arrangements, or value based billing, that takes a creative 'risk sharing' attitude, utilizing fee arrangements that I believe may  better align the firm's interests with our clients," said Stronski.

Stronski received his B.A. from Dartmouth College and his J.D. from Fordham Law School. After graduation from Fordham, Stronski completed a two-year clerkship for the Honorable Shirley W. Kram of the U.S. District Court for the Southern District of New York.

Suzuki, a New York-based counsel in the firm's Intellectual Property Group, focuses her practice on patent litigation, primarily related to pharmaceutical litigation under the Hatch-Waxman Act. Prior to private practice, Suzuki worked in technology transfer at the Office of Industrial Liaison at Mount Sinai School of Medicine. She received her B.A. from Bryn Mawr College, M.A. in Biotechnology from Columbia University, and her J.D. from University of California, Hastings College of Law.

Crowell & Moring LLP is an international law firm with nearly 500 lawyers representing clients in litigation and arbitration, regulatory, and transactional matters. The firm is internationally recognized for its representation of Fortune 500 companies in high-stakes litigation, as well as its ongoing commitment to pro bono service and diversity. The firm has offices in Washington, DC, New York, Los Angeles, San Francisco, Orange County, Anchorage, London, and Brussels. Visit Crowell & Moring online at www.crowell.com.

Contact:   Jessica O'Neil
(202) 508-8750
joneil@crowell.com


'/>"/>
SOURCE Crowell & Moring LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... Research and Markets has announced the addition of the ... their offering. ... Cystic fibrosis (CF) is a progressive genetic condition and is the ... regulator (CFTR) gene from both parents. The defective CFTR genes produce ... the buildup of a thick and sticky mucus in the lungs ...
(Date:1/13/2017)... , Jan. 12, 2017  Albertsons Companies proudly ... Commission for Health Care (ACHC) for its specialty ... food and drug chain with this accreditation and ... patients. Accreditation by ACHC reflects Albertsons ... to facilitate a higher level of performance and ...
(Date:1/13/2017)... , Jan. 13, 2017  Biologics Prescribers ... Drug Administration (FDA) for issuing final guidance ... medicines. This policy is an important win ... is essential for pharmacovigilance, patient safety and ... has voiced to FDA, we remain concerned with "random" ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... , ... Whole Health Supply, LLC is announcing the release of an updated version of their ... , The 2017 edition has wide jaws that will accommodate nails up to 4mm ... as diabetics. This handle is reinforced for extra strength when pressing down on dense nails ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... The Gravity ... location in Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing ... Gravity Vaults sixth location, including three in New Jersey and two in New York. ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... frame transition from one clip to the next. , To use “Cut-Out First” ...
(Date:1/13/2017)... ... 2017 , ... With the increasing public preference for chemical-free ... organic alternatives for customers who have grown more conscious about maintaining their health ... activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s ...
(Date:1/13/2017)... , ... January 13, 2017 , ... Friday, January 13 ... of the game room, increasing the size of the location to 90,000 square feet. ... 8-hole mini golf course that takes customers on an educational tour of the historic ...
Breaking Medicine News(10 mins):